Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Immunoradiation for Stage III Resectable Non-Small Cell Lung Cancer
NCT03237377Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2017
- Primary completion
- Nov 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
Phase 2, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Toxicities as Measured by Number of Participants Experiencing Adverse Events and Feasibility of Preoperative Immunoradiation up to 3 years. Started Dec 2017; status: terminated.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03237377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237377.